Cumberland Pharmaceuticals Inc. (CPIX) Income Statement Analysis

See more : IF Bancorp, Inc. (IROQ) Income Statement Analysis – Financial Results

Complete financial analysis of Cumberland Pharmaceuticals Inc. (CPIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cumberland Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Suzhou SLAC Precision Equipment CO.,Ltd. (300382.SZ) Income Statement Analysis – Financial Results
Banpu Public Company Limited (BANPU-R.BK) Income Statement Analysis – Financial Results
Devine Impex Limited (DEVINE.BO) Income Statement Analysis – Financial Results
Pollard Banknote Limited (PBL.TO) Income Statement Analysis – Financial Results
Lar España Real Estate SOCIMI, S.A. (LRE.MC) Income Statement Analysis – Financial Results

Cumberland Pharmaceuticals Inc. (CPIX)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.cumberlandpharma.com

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	39.55M	42.01M	35.99M	37.44M	34.39M	40.74M	41.15M	33.03M	33.52M	36.90M	32.03M	48.85M	51.14M	45.88M	43.54M	35.08M	28.06M	17.82M	10.69M
Cost of Revenue	6.07M	9.12M	8.81M	8.65M	7.42M	7.38M	7.37M	5.96M	4.97M	5.05M	5.44M	5.05M	5.36M	3.59M	4.14M	3.05M	2.67M	2.40M	533.26K
Gross Profit	33.49M	32.89M	27.17M	28.79M	26.97M	33.36M	33.78M	27.07M	28.55M	31.85M	26.59M	43.81M	45.78M	42.29M	39.40M	32.03M	25.39M	15.42M	10.16M
Gross Profit Ratio	84.66%	78.29%	75.51%	76.89%	78.42%	81.89%	82.09%	81.96%	85.18%	86.31%	83.02%	89.67%	89.51%	92.18%	90.50%	91.32%	90.49%	86.53%	95.01%
Research & Development	5.83M	6.69M	5.68M	5.77M	6.87M	7.32M	3.90M	3.19M	3.85M	3.39M	5.62M	5.10M	5.03M	4.33M	4.99M	4.43M	3.69M	2.23M	1.16M
General & Administrative	10.65M	10.18M	9.78M	10.20M	9.97M	10.41M	10.03M	8.56M	7.61M	8.40M	9.49M	9.10M	9.20M	7.99M	7.64M	5.14M	4.14M	3.00M	2.59M
Selling & Marketing	18.45M	16.66M	15.02M	14.77M	15.28M	20.26M	21.49M	14.55M	13.99M	14.90M	14.39M	20.33M	20.94M	22.67M	20.19M	14.39M	10.05M	7.35M	5.65M
SG&A	29.10M	26.84M	24.80M	24.96M	25.25M	30.66M	31.52M	23.12M	21.60M	23.30M	23.88M	29.43M	30.14M	30.66M	27.84M	19.53M	14.19M	10.35M	8.24M
Other Expenses	8.10M	5.07M	4.37M	4.43M	4.13M	2.77M	2.44M	2.19M	1.99M	1.60M	896.16K	466.13K	655.30K	686.91K	793.68K	791.11K	783.43K	611.61K	13.49K
Operating Expenses	39.39M	38.60M	34.85M	35.17M	36.26M	40.75M	37.86M	28.50M	27.44M	28.29M	30.39M	34.99M	35.93M	35.79M	33.62M	24.75M	18.67M	13.19M	9.41M
Cost & Expenses	45.46M	47.72M	43.66M	43.82M	43.68M	48.13M	45.23M	34.46M	32.41M	33.34M	35.83M	40.03M	41.29M	39.37M	37.76M	27.79M	21.34M	15.59M	9.94M
Interest Income	286.85K	98.41K	26.08K	75.35K	243.36K	564.48K	299.33K	204.66K	209.18K	251.45K	230.29K	304.87K	210.73K	200.21K	79.36K	241.28K	382.92K	208.68K	89.24K
Interest Expense	667.86K	586.00K	98.03K	263.63K	246.19K	195.85K	92.90K	106.39K	73.86K	67.07K	103.42K	71.99K	353.50K	1.42M	772.93K	213.30K	639.59K	721.80K	63.20K
Depreciation & Amortization	5.77M	5.33M	4.61M	4.75M	4.40M	2.98M	2.65M	2.40M	2.25M	1.99M	1.30M	901.65K	1.04M	978.40K	816.50K	786.60K	762.22K	587.74K	53.54K
EBITDA	153.32K	332.92K	-857.83K	-1.56M	-4.64M	-8.19M	-1.13M	1.17M	3.57M	5.73M	-2.27M	10.02M	11.00M	7.68M	6.67M	8.31M	7.87M	3.02M	882.39K
EBITDA Ratio	0.39%	-0.66%	-2.38%	-4.16%	-13.49%	-9.43%	-2.76%	3.54%	10.64%	15.72%	-7.09%	20.52%	21.71%	16.74%	15.33%	23.69%	28.05%	16.92%	8.25%
Operating Income	-6.21M	-5.70M	-7.68M	-6.38M	-9.29M	-7.39M	-4.08M	-1.43M	-1.11M	3.56M	-3.80M	8.82M	9.85M	6.50M	5.78M	7.28M	6.73M	2.22M	749.92K
Operating Income Ratio	-15.70%	-13.58%	-21.34%	-17.04%	-27.01%	-18.14%	-9.92%	-4.34%	-3.32%	9.64%	-11.87%	18.05%	19.26%	14.17%	13.27%	20.76%	23.96%	12.48%	7.02%
Total Other Income/Expenses	-74.18K	123.74K	2.12M	-188.28K	-2.82K	368.64K	206.42K	98.27K	135.33K	184.37K	126.87K	232.88K	-142.77K	-1.22M	-693.56K	27.98K	-256.67K	-515.93K	20.40K
Income Before Tax	-6.28M	-5.58M	-5.56M	-6.57M	-9.29M	-7.02M	-3.87M	-1.33M	1.25M	3.74M	-3.67M	9.05M	9.71M	5.28M	5.08M	7.31M	6.47M	1.71M	770.32K
Income Before Tax Ratio	-15.89%	-13.29%	-15.46%	-17.55%	-27.02%	-17.24%	-9.42%	-4.04%	3.72%	10.14%	-11.47%	18.53%	18.98%	11.51%	11.68%	20.84%	23.05%	9.59%	7.21%
Income Tax Expense	45.77K	68.85K	34.89K	55.90K	-79.32K	16.64K	4.17M	-330.92K	575.83K	1.38M	-1.52M	3.24M	4.08M	2.85M	2.02M	2.54M	2.42M	-2.70M	-1.18M
Net Income	-6.28M	-5.65M	-5.60M	-6.63M	-9.21M	-6.96M	-7.98M	-944.68K	731.35K	2.42M	-2.10M	5.84M	5.66M	2.46M	3.09M	4.77M	4.04M	4.40M	1.95M
Net Income Ratio	-15.88%	-13.45%	-15.55%	-17.70%	-26.79%	-17.09%	-19.39%	-2.86%	2.18%	6.57%	-6.57%	11.96%	11.06%	5.36%	7.10%	13.59%	14.41%	24.72%	18.28%
EPS	-0.44	-0.39	-0.38	-0.44	-0.60	-0.45	-0.50	-0.06	0.04	0.14	-0.11	0.30	0.28	0.12	0.22	0.47	0.40	0.45	0.21
EPS Diluted	-0.44	-0.39	-0.38	-0.44	-0.60	-0.45	-0.50	-0.06	0.04	0.14	-0.11	0.30	0.28	0.12	0.17	0.29	0.24	0.27	0.12
Weighted Avg Shares Out	14.30M	14.56M	14.90M	15.16M	15.40M	15.57M	15.91M	15.74M	16.72M	17.62M	18.33M	19.56M	20.34M	20.33M	14.20M	10.14M	10.03M	9.80M	9.50M
Weighted Avg Shares Out (Dil)	14.30M	14.56M	14.90M	15.16M	15.40M	15.61M	15.91M	16.24M	17.09M	17.90M	18.33M	19.79M	20.57M	21.06M	18.23M	16.54M	16.58M	16.45M	16.09M

Cumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update

May 11, 2021prnewswire.com

NASHVILLE, Tenn., May 11, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and first quarter 2021 financial results.

Preview: Cumberland's Earnings

May 10, 2021benzinga.com

Cumberland (NASDAQ:CPIX) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's look at Cumberland's Q1 earnings report.

Providence's Tegria adds another company, acquires healthcare consulting firm Cumberland

March 16, 2021geekwire.com

Seattle-based Tegria, a healthcare services and tech company that Providence launched last year, announced the acquisition of Franklin, Tenn.

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q4 2020 Results - Earnings Call Transcript

March 9, 2021seekingalpha.com

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q4 2020 Results - Earnings Call Transcript

Cumberland Pharmaceuticals (CPIX) Beats Q4 Earnings and Revenue Estimates

March 9, 2021zacks.com

Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020

March 9, 2021prnewswire.com

NASHVILLE, Tenn., March 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results.

Cumberland Earnings Preview

March 8, 2021benzinga.com

Cumberland (NASDAQ:CPIX) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's look at Cumberland's Q4 earnings report.

Where Do Hedge Funds Stand On Cumberland Pharmaceuticals, Inc. (CPIX)?

November 27, 2020insidermonkey.com

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos...

Introducing RediTrex®, A New Methotrexate Delivery System

November 17, 2020prnewswire.com

NASHVILLE, Tenn., Nov. 17, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announced today the launch of RediTrex® (methotrexate) injection. RediTrex is a new line of pre-filled syringes specifically designed for ease of...